The Subject Expert Committee (SEC) on Haematology has recommended for grant of permission to conduct a Phase-III clinical ...

Zydus Lifesciences is on analysts' radar. The stock rose nearly 2% on Wednesday after reporting mixed fourth-quarter results.

After a record FY25, the drugmaker sees new growth engines in biologics, vaccines, and devices powering expansion in FY26.

Zydus Lifesciences Q4 stuns with margin guidance, but brokerages trim targets — stock ends at Rs 890. Should you follow ...

Zydus Wellness unveils new brand identity, reports strong financial growth, and focuses on science-backed innovation and ...

Zydus Wellness introduces a refreshed corporate brand identity, signaling a commitment to science-backed, consumer-centric ...

The company's net profit was at Rs 1,182 crore, with revenue at Rs 5,633 crore and EBITDA margin rising to 26.7 percent, in ...

Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 970 in its research report ...

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter ...

Zydus Wellness unveils a new corporate brand identity to reinforces its science-led purpose: Our Bureau, Bengaluru Wednesday, May 21, 2025, 15:40 Hrs [IST] Zydus Wellness has unve ...

Margin expansion will be a key focus for the company, with a long-term goal of reaching 17-18%, supported by operating ...

The identity refresh positions Zydus Wellness as an organization rooted in science, driven by compassion, and inspired by the ...